ReviewHepatology communications2017
Drug-induced cholestasis.
Review in Hepatology communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.Alimentary pharmacology & therapeutics · 2020Guideline
- Application of metabolomics in drug-induced liver injury: A systematic review.Journal of translational internal medicine · 2026Article
- A newFrontiers in toxicology · 2026Article
- Non-medical use of exogenous testosterone and anabolic-androgenic substances in young men: health, psychological, and fertility consequences.Frontiers in endocrinology · 2026Review
- Drug-Induced Liver Injury Secondary to Meropenem: Diagnostic Challenge and Therapeutic Role of Hemoadsorption.Cureus · 2025Article
- Are We Considering All the Potential Drug-Drug Interactions in Women's Reproductive Health? A Predictive Model Approach.Pharmaceutics · 2025Article
- Refining Drug-Induced Cholestasis Prediction: An Explainable Consensus Model Integrating Chemical and Biological Fingerprints.Journal of chemical information and modeling · 2025Article
- Drug Reaction With Eosinophilia and Systemic Symptoms and Severe Drug-Induced Liver Injury After Off-Label Zonisamide Use for Weight Loss.ACG case reports journal · 2025Article
- Mechanisms of drug induced liver injury.Cellular and molecular life sciences : CMLS · 2025Review
- Genotypes and different clinical variants between children and adults in progressive familial intrahepatic cholestasis: a state-of-the-art review.Orphanet journal of rare diseases · 2025Review
- Pharmacist-Led Assessment of Drug-Induced Liver Injury in Hospitalized Patients.The Canadian journal of hospital pharmacy · 2025Article
- When a Budget-Friendly Drug Leads to a Premium Diagnosis: A Case Report of Severe Cholestasis Following Amoxicillin-Clavulanate Use.Case reports in hepatology · 2025Article
- Acquired ductopenia: an insight into imaging findings.Abdominal radiology (New York) · 2025Review
- From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling.Archives of toxicology · 2024Article
- Regular Consumption of Green Tea as an Element of Diet Therapy in Drug-Induced Liver Injury (DILI).Nutrients · 2024Review
- Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report With Review of the Literature.Cureus · 2024Article
- Integrated multi-omics analyses combined with western blotting discovered that cis-TSG alleviated liver injury via modulating lipid metabolism.Frontiers in pharmacology · 2024Article
- Severe liver injury induced by minocycline in hepatitis B patient: a Case Report.Frontiers in pharmacology · 2024Article
- Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition.Clinical science (London, England : 1979) · 2023Article
- COVID-19 related biliary injury: A review of recent literature.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug-induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.